THE INNATE IMMUNITY COMPANY Trademark

Trademark Overview

On Friday, March 30, 2012, a trademark application was filed for THE INNATE IMMUNITY COMPANY with the United States Patent and Trademark Office. The USPTO has given the THE INNATE IMMUNITY COMPANY trademark a serial number of 85584502. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, October 18, 2019. This trademark is owned by Celtaxsys, Inc.. The THE INNATE IMMUNITY COMPANY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development
the innate immunity company

General Information

Serial Number85584502
Word MarkTHE INNATE IMMUNITY COMPANY
Filing DateFriday, March 30, 2012
Status710 - CANCELLED - SECTION 8
Status DateFriday, October 18, 2019
Registration Number4302991
Registration DateTuesday, March 12, 2013
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Disclaimer with Predetermined Text"COMPANY"
Goods and ServicesPharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, October 18, 2019
Primary Code042
First Use Anywhere DateThursday, April 12, 2012
First Use In Commerce DateThursday, April 12, 2012

Trademark Owner History

Party NameCeltaxsys, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAtlanta, GA 30332
Party NameCeltaxsys, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAtlanta, GA 30332

Trademark Events

Event DateEvent Description
Friday, October 18, 2019CANCELLED SEC. 8 (6-YR)
Monday, March 12, 2018COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, March 12, 2013REGISTERED-SUPPLEMENTAL REGISTER
Wednesday, February 6, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, February 6, 2013ASSIGNED TO LIE
Wednesday, February 6, 2013APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Wednesday, February 6, 2013EXAMINER'S AMENDMENT ENTERED
Wednesday, February 6, 2013NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, February 6, 2013EXAMINERS AMENDMENT E-MAILED
Wednesday, February 6, 2013EXAMINERS AMENDMENT -WRITTEN
Tuesday, January 15, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 15, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 15, 2013ASSIGNED TO LIE
Tuesday, January 15, 2013NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Monday, January 14, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 14, 2013USE AMENDMENT ACCEPTED
Saturday, January 12, 2013AMENDMENT TO USE PROCESSING COMPLETE
Saturday, January 12, 2013USE AMENDMENT FILED
Friday, January 11, 2013TEAS AMENDMENT OF USE RECEIVED
Thursday, July 12, 2012NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 12, 2012NON-FINAL ACTION E-MAILED
Thursday, July 12, 2012NON-FINAL ACTION WRITTEN
Thursday, July 12, 2012ASSIGNED TO EXAMINER
Thursday, April 5, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 3, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

company immunity innate development research pharmaceutical